PharmaTimesOriginal article
Polpharma Biologics gains FDA and EMA review acceptances
RegulatoryPB016Positive
AI Analysis
Summary
Polpharma Biologics announced that FDA and EMA have accepted applications for review of PB016, a vedolizumab biosimilar candidate. The regulatory acceptances represent a positive regulatory milestone in the development pathway.
Outcome Details
FDA and EMA review acceptances for PB016 vedolizumab biosimilar applications
Importance:6/10
Sentiment:
0.60
FDA approval processEMA approval processbiosimilarvedolizumabregulatory milestone
Read the original article
Published by PharmaTimes on August 3, 2026 11:03 AM